{'fraction_non_alphanumeric': 0.03287890938251804, 'fraction_numerical': 0.03929430633520449, 'mean_word_length': 6.0508474576271185, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Esophageal Cytoprotection in Rats. Stable Gastric Pentadecapeptide BPC 157 and Omeprazole

Up to now, esophagus, as a direct target, is not particularly concerned in stomach cytoprotection studies performed with direct instillation of the nocuous agent in the rat stomach (Curr Pharm Des 2010;16(10):1224–34). Therefore, using intraesophageal administration of various nocuous irritants, and then, intraesophageal administration of medication in rats, we hypothesize the stable gastric pentadecapeptide BPC 157 to induce direct cytoprotection in esophagus. BPC 157 was originally an anti‐ulcer peptide used in trials for ulcerative colitis and now is in trials for the treatment of multiple sclerosis that largely interacts with NO‐system (Curr Pharm Des 2014;20(7):1126–35) and thought to be novel mediator of Robert's cytoprotection in rat stomach studies, known to exert an immediate endothelium protection alongside with mucosal protection in stomach, known to counteract variously induced gastrointestinal lesions in various species, and thereby suited for the necessary generalization of the concept of the stomach cytoprotection to the entire gastrointestinal tract, and to the esophagus, in particular (Curr Pharm Des. 2014;20(7):1126–35).